FDA Commissioner Hahn Addresses AdvaMed Board of Directors on Coronavirus
March 17, 2020
WASHINGTON, D.C. – FDA Commissioner Dr. Stephen Hahn joined a special meeting of AdvaMed’s Board of Directors today to discuss how the medical technology industry and FDA can continue their work together to ensure patients and health care providers have the medical equipment they need to address the COVID-19 pandemic.
“I thank FDA Commissioner Hahn for taking the time to speak to leaders from across the medical technology industry about how we can best continue our work together to combat COVID-19,” said Chairman and CEO of Stryker and AdvaMed Chairman Kevin Lobo. “The medical technology community is doing everything we can to help treat and stop the spread of the coronavirus, and I appreciate the tremendous work the industry is doing.”
“It was important for our board of directors to hear directly from the Commissioner on all the work FDA is doing in partnership with our industry to fight COVID-19. We thank him for taking the time and for his remarkable and steady leadership during this time of crisis,” said AdvaMed President and CEO Scott Whitaker. “Dr. Hahn reiterated the importance of the medtech industry to this fight and to the American people who depend on our innovators and manufacturers. We take that responsibility very seriously. Our board meeting today focused almost exclusively on the industry’s coronavirus efforts. It was productive, exhaustive, and we look forward to continuing our work to get the medical technologies essential to this fight where they’re needed most.”
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.